2seventy bio Statistics
Share Statistics
2seventy bio has 51.59M shares outstanding. The number of shares has increased by 1.73% in one year.
| Shares Outstanding | 51.59M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.18% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 48.33M |
| Failed to Deliver (FTD) Shares | 3 |
| FTD / Avg. Volume | 0% |
Short Selling Information
The latest short interest is 5.41M, so 10.51% of the outstanding shares have been sold short.
| Short Interest | 5.41M |
| Short % of Shares Out | 10.51% |
| Short % of Float | 11.22% |
| Short Ratio (days to cover) | 23.15 |
Valuation Ratios
The PE ratio is -0.97 and the forward PE ratio is -10.39.
| PE Ratio | -0.97 |
| Forward PE | -10.39 |
| PS Ratio | 2.1 |
| Forward PS | 2.3 |
| PB Ratio | 0.82 |
| P/FCF Ratio | -1.16 |
| PEG Ratio | n/a |
Enterprise Valuation
2seventy bio Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 3.98, with a Debt / Equity ratio of 1.01.
| Current Ratio | 3.98 |
| Quick Ratio | 3.98 |
| Debt / Equity | 1.01 |
| Total Debt / Capitalization | 50.13 |
| Cash Flow / Debt | -0.65 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.85% and return on capital (ROIC) is -42.33%.
| Return on Equity (ROE) | -0.85% |
| Return on Assets (ROA) | -0.38% |
| Return on Capital (ROIC) | -42.33% |
| Revenue Per Employee | 366.38K |
| Profits Per Employee | -794.05K |
| Employee Count | 274 |
| Asset Turnover | 0.18 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -12.57% in the last 52 weeks. The beta is 1.79, so 2seventy bio 's price volatility has been higher than the market average.
| Beta | 1.79 |
| 52-Week Price Change | -12.57% |
| 50-Day Moving Average | 4.3 |
| 200-Day Moving Average | 4.5 |
| Relative Strength Index (RSI) | 37.37 |
| Average Volume (20 Days) | 306.92K |
Income Statement
In the last 12 months, 2seventy bio had revenue of $100.39M and earned -$217.57M in profits. Earnings per share was $-4.42.
| Revenue | 100.39M |
| Gross Profit | 83.47M |
| Operating Income | -216.70M |
| Net Income | -217.57M |
| EBITDA | -206.42M |
| EBIT | -216.70M |
| Earnings Per Share (EPS) | -4.42 |
Balance Sheet
The company has $74.96M in cash and $256.67M in debt, giving a net cash position of -$181.72M.
| Cash & Cash Equivalents | 74.96M |
| Total Debt | 256.67M |
| Net Cash | -181.72M |
| Retained Earnings | -511.22M |
| Total Assets | 503.85M |
| Working Capital | 174.38M |
Cash Flow
In the last 12 months, operating cash flow was -$166.86M and capital expenditures -$13.87M, giving a free cash flow of -$180.72M.
| Operating Cash Flow | -166.86M |
| Capital Expenditures | -13.87M |
| Free Cash Flow | -180.72M |
| FCF Per Share | -3.67 |
Margins
Gross margin is 83.15%, with operating and profit margins of -215.87% and -216.73%.
| Gross Margin | 83.15% |
| Operating Margin | -215.87% |
| Pretax Margin | -216.73% |
| Profit Margin | -216.73% |
| EBITDA Margin | -205.62% |
| EBIT Margin | -215.87% |
| FCF Margin | -180.03% |
Dividends & Yields
TSVT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -135.17% |
| FCF Yield | -107.13% |
Analyst Forecast
The average price target for TSVT is $11, which is 236.4% higher than the current price. The consensus rating is "Hold".
| Price Target | $11 |
| Price Target Difference | 236.4% |
| Analyst Consensus | Hold |
| Analyst Count | 6 |
Scores
| Altman Z-Score | -1.57 |
| Piotroski F-Score | 1 |